Wall Street's Underestimation of Tempus AI: A Moat Worth Defending? Tempus AI, Inc.
's (NASDAQ:TEM) recent $80 price target from Cantor Fitzgerald has sparked debate about whether Wall Street is underestimating the company's healthcare data moat.
This argument centers on a combination of clinical data, diagnostics, software, and artificial intelligence operating inside healthcare workflows – a difficult to replicate advantage that Tempus AI aims to build upon.